News
Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to trac ...
Zacks Investment Research on MSN6d
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the StockBioCryst Pharmaceuticals BCRX is slated to report its second-quarter 2025 results on Aug. 4, before the opening bell. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback